RAB9B

Across TCGA pan-cancer cohorts, RAB9B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RAB9B data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RAB9B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAB9B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM and PDAC are the cancer types where RAB9B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.802	0.662	.023	6	view →
PDAC	DFS	Median	All	0.307	0.984	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RAB9B–GBM (DFS)

Open the GBM breakdown →